Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Tsumura & Co ( (JP:4540) ).
Tsumura & Co. has concluded a contract to acquire shares of Yomeishu Seizo Co., Ltd., aligning the deal with its long-term TSUMURA VISION “Cho-WA” 2031 strategy. The vision emphasizes contributing to a healthier society by developing evidence-based diagnostic methods for pre-symptomatic diseases and delivering Kampo and traditional Chinese medicine solutions tailored to personal health conditions.
The acquisition supports Tsumura’s ambition to expand its footprint in traditional medicine while reinforcing a corporate culture that values dialogue and employee potential. By integrating Yomeishu Seizo into its broader strategy, Tsumura aims to strengthen its unique positioning in Kampo and traditional Chinese medicine, enhancing its role in preventive healthcare and personalized well-being services.
The most recent analyst rating on (JP:4540) stock is a Buy with a Yen4762.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
More about Tsumura & Co
Tsumura & Co. operates in the pharmaceutical and healthcare sector, focusing on Kampo and traditional Chinese medicine. The company aims to provide evidence-based treatments and services tailored to individual life stages, symptoms, genetic profiles, and living environments, with an emphasis on building a healthy society and a supportive, dialogue-driven corporate culture.
Average Trading Volume: 309,649
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen311.7B
Learn more about 4540 stock on TipRanks’ Stock Analysis page.